LAS VEGAS, Nov. 15, 2018 /PRNewswire/ -- Digipath, Inc. (OTCQB: DIGP), a service-oriented independent testing laboratory and data firm focused on the developing cannabis market, is pleased to announce that its newest Board Member and Chief Science Officer, Dr. Cindy Orser, was asked to speak on Cannabinoids and Terpenes at the 2018 MJBizCon Science Symposium in Las Vegas this week, as part of the largest cannabis conference in the world.
Dr. Orser has been a leader in bringing transparency to the cannabis consumer by distilling analytical findings from chemical profiling of thousands of cannabis samples at Digipath Labs in Las Vegas, NV where she serves as the Chief Science Officer. One of her primary focuses has been replacing the present use of slang titles for strain naming in lieu of giving Cannabis sativa proper cultivar names based on defined parentage and chemoprofiling. Dr. Orser's other focus has been her analytical research on cannabis terpenoid profiles and keen interest in assigning further physiological meaning to individual terpenoids.
Dr. Orser's important work at Digipath is providing a technical foundation for understanding, proper cultivation and quality of product for the end consumer.
"I was given the opportunity two years ago to deliver the opening "Cannabis Science" keynote at the MJBizCon Science Symposium and learned so much researching, organizing and delivering my talk that I was eager to do a repeat this year," stated Dr. Orser. "It is important that the cannabis business community understand what we are doing at Digipath and how it can be a catalyst to their own business models and the well-being of this industry."
"Cindy provides an exceptional voice in educating the public and other scientists on new and exciting information with this incredible plant," stated Todd Denkin, President and CEO of Digipath. "We are incredibly grateful to have one of the industry's leading scientists and true pioneers officiating our technology and the commercial services we provide. If you get the chance to here Cindy speak you should take it!"
About Digipath, Inc. & Digipath Labs, Inc.
Digipath, Inc. supports the cannabis industry's best practices for reliable testing, data acquisition, cannabis education and training, and brings unbiased cannabis news coverage to the cannabis industry. Digipath Labs provides pharmaceutical-grade analysis and testing to the cannabis industry to ensure producers, consumers, and patients know exactly what is in the cannabis they ingest and to help maximize the quality of its client's products through analysis, research, development, and standardization.
Digipath Investor Relations & Financial Media
info@integrityir.com
Toll Free: (888) 216-3595
www.IntegrityIR.com
Information about Forward-Looking Statements
This press release contains "forward-looking statements" that include information relating to future events. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management's good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in, or suggested by, the forward-looking statements. Important factors that could cause these differences include, but are not limited to: the Company's need for additional funding, the demand for the Company's products, governmental regulation of the cannabis industry, the Company's ability to maintain customer and strategic business relationships, the impact of competitive products and pricing, growth in targeted markets, the adequacy of the Company's liquidity and financial strength to support its growth, and other risks that may be detailed from time-to-time in the Company's filings with the United States Securities and Exchange Commission. For a more detailed description of the risk factors and uncertainties affecting Digipath, please refer to the Company's recent Securities and Exchange Commission filings, which are available at www.sec.gov. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
SOURCE Digipath, Inc.
